The US nonprescription antiseptics industry is forging ahead with studies to support general recognition of safety and effectiveness (GRASE) for priority germ-killing agents that the US Food and Drug Administration has identified as insufficiently studied, putting them at risk of being deemed unapproved new drugs.
The FDA issued final rules for OTC consumer antiseptic washes, consumer antiseptic rubs and health care antiseptics in September 2016, April 2019 and December 2017, respectively, deferring rulemaking on six...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?